Cibc World Markets Corp Raises Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Cibc World Markets Corp increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 13.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,614 shares of the medical equipment provider's stock after buying an additional 3,854 shares during the quarter. Cibc World Markets Corp's holdings in Zimmer Biomet were worth $3,339,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Roman Butler Fullerton & Co. bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at about $473,000. Geode Capital Management LLC boosted its position in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after buying an additional 125,852 shares during the period. M&T Bank Corp grew its holdings in Zimmer Biomet by 48.4% in the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock worth $2,884,000 after acquiring an additional 8,709 shares during the last quarter. KLCM Advisors Inc. purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $7,825,000. Finally, Peddock Capital Advisors LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at about $654,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Down 0.7 %

Zimmer Biomet stock traded down $0.74 during mid-day trading on Tuesday, hitting $110.50. The company had a trading volume of 1,296,857 shares, compared to its average volume of 1,496,400. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The stock's 50 day moving average price is $106.86 and its two-hundred day moving average price is $106.86. The company has a market capitalization of $22.00 billion, a PE ratio of 24.83, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04.

Remove Ads

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm earned $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.57%.

Analysts Set New Price Targets

ZBH has been the topic of a number of research analyst reports. Stifel Nicolaus boosted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a report on Thursday, January 23rd. JPMorgan Chase & Co. raised Zimmer Biomet from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Raymond James dropped their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. JMP Securities reissued a "market outperform" rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $124.15.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.95% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.